An observational study in Breast Cancer, Post-Operative Hematoma and Seroma as Procedural Complication, sponsored by Seoul National University Hospital. Not yet recruiting. Open to female participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Seoul National University Hospital · Observational
The investigators aim to compare the incidence rates of seroma (fluid collection) and hematoma (blood clot) following breast cancer surgery between the conventional non-steroidal anti-inflammatory drug (NSAID) Ketorolac and MAXIGESIC. The investigators seek to determine the complication rates in patients receiving MAXIGESIC post-surgery, hypothesizing that the higher dosage of ibuprofen in MAXIGESIC compared to Ketorolac will result in lower complication rates.
Among patients who underwent breast cancer surgery at Seoul National University Hospital from January 1, 2023 to December 31, 2023, 127 patients were prescribed ketorolac and wore compression dressings. The number of patients was calculated to be approximately 60 to collect basic data to confirm the feasibility of conducting the main study.
Exclusion Criteria:
Maxigesig group
ketololac group
Postoperative hemovac or JP total drainage amount
Postoperative hemovac or JP total drainage amount
Time frame: within 3 months
hematoma incidence
hematoma incidence
Time frame: within 3 months
Seroma incidence
Seroma incidence
Time frame: within 3 months
Length of hospital stay
Length of hospital stay and re operation rate
Time frame: within 3 months
Complication
* When hematoma occurs: Whether transfusion is required and whether EB band is applied, check the amount when aspirating (diagnosis criteria color: sanguinous, old bloody \[brownish\], operation (hematoma evacuation) * When seroma occurs: check the amount when aspirating (diagnosis criteria color: serous, serosanguinous) * Complication: Whether abscess occurs
Time frame: within 3 months
No study locations are listed for this record.
This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital